Safe utilization of ruxolitinib in simultaneous primary myelofibrosis and warm autoimmune hemolytic anemia

Ann Hematol. 2024 Feb;103(2):677-679. doi: 10.1007/s00277-023-05535-5. Epub 2023 Nov 6.

Authors

Victor Pope¹, Cyrus C Hsia²

Affiliations

¹ Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
² Department of Medicine, Division of Hematology,, London Health Sciences Centre, Room E6-219A, Victoria Hospital, 800 Commissioners Road East, London, Ontario, Canada. cyrus.hsia@lhsc.on.ca.

PMID: 37930364
DOI: 10.1007/s00277-023-05535-5

No abstract available

Publication types

Letter

MeSH terms

Anemia, Hemolytic, Autoimmune* / drug therapy
Humans
Nitriles
Primary Myelofibrosis* / complications
Primary Myelofibrosis* / drug therapy
Pyrazoles*
Pyrimidines

Substances

ruxolitinib
Nitriles
Pyrimidines
Pyrazoles